Vertex Pharmaceuticals
NASDAQ: VRTX
Vertex Pharmaceuticals is a biotechnology company that develops and commercializes medicines for serious diseases. Its core business focuses on cystic fibrosis treatments, with additional products for sickle cell disease, beta thalassemia and acute pain. Its expanding portfolio and drug development pipeline are key areas analysts evaluate.
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Employees
- 6,400
- Founded
- 1989
- Website
- vrtx.com ↗
The forecast figures are tipranks’s, read on 2026-10-26 and linked below.
The company facts and financials are CNN Business’s, read on 2026-11-16 and linked below.
Vertex Pharmaceuticals forecast
The forecast in short
tipranks records 24 analyst ratings on Vertex Pharmaceuticals and summarises them as “Strong Buy”. Their average 12-month price target is USD 589.45 (Potential Growth = 12.51%). Its tipranks score is 8 out of 10 — Outperform. These are tipranks’s figures as read on 2026-10-26, not CariBroker’s own view, and nothing here is advice to buy or sell.
Market cap
USD 136.01 B
≈ RM 556.36 B
Share price
USD 536.45
≈ RM 2194.40 · 18 Nov close
#163World ranking
tipranks score
Outperform
Analyst ratings
Strong Buy
- Buy2188%
- Hold313%
- Sell00%
tipranks’s own summary of the 24 ratings above.
12 months price forecast
USD 589.45 Potential Growth = 12.51%
As tipranks publishes it. CariBroker has not recalculated any of it.
Financials
Q3 earnings, quarter ending Sep 29, 2026
| Measure | Q3 2026 | 1-year change |
|---|---|---|
| Total revenue | 3.44B | 6.57% up |
| Net income | 653.60M | 45.13% down |
| Earnings per share | 2.56 | 39.08% down |
| Net profit margin | 19.01% | 45.32% down |
| Free cash flow | 545.80M | 56.57% up |
| Debt-to-equity ratio | 0.31 | 192.48% up |
Revenue and net income, last 4 quarters
Total revenueNet income
Analyst profiles: who made each call, and when
| Analyst | From | Position | Target price | Dated |
|---|---|---|---|---|
| Michael Yee | UBS | Buy | USD 615 | 2026-10-24 |
| Geoff Meacham | Citi | Buy | USD 585 | 2026-10-19 |
| Tazeen Ahmad | Bank of America Securities | Buy | USD 667 | 2026-10-16 |
| Mohit Bansal | Wells Fargo | Buy | USD 550 | 2026-10-15 |
| Evan Seigerman | BMO Capital | Buy | USD 600 | 2026-10-12 |
Show all 30
| Analyst | From | Position | Target price | Dated |
|---|---|---|---|---|
| Brian Abrahams | RBC Capital | Buy | USD 576 | 2026-10-08 |
| Terence Flynn | Morgan Stanley | Buy | USD 665 | 2026-10-07 |
| Jeffrey Walch | Bernstein | Buy | USD 608 | 2026-09-25 |
| Eliana Merle | Barclays | Buy | USD 617 | 2026-09-23 |
| Danielle Brill | Truist Financial | Buy | N/A | 2026-09-23 |
| Whitney Ijem | Canaccord Genuity | Hold | USD 442 | 2026-09-23 |
| Louise Chen | Scotiabank | Buy | USD 558 | 2026-09-23 |
| Akash Tewari | Jefferies | Buy | USD 640 | 2026-09-23 |
| Paul Matteis | Stifel Nicolaus | Hold | N/A | 2026-09-22 |
| Salveen Richter | Goldman Sachs | Buy | USD 653 | 2026-09-22 |
| Andrew Fein | H.C. Wainwright | Buy | USD 641 | 2026-09-22 |
| Myles Minter | William Blair | Buy | N/A | 2026-09-22 |
| Jessica Fye | J.P. Morgan | Buy | USD 560 | 2026-09-11 |
| Naz Rahman | Maxim Group | Buy | USD 575 | 2026-08-05 |
| Phil Nadeau | TD Cowen | Buy | USD 550 | 2026-08-04 |
| Carter Gould | Cantor Fitzgerald | Buy | USD 595 | 2026-08-04 |
| Joseph Stringer | Needham | Hold | N/A | 2026-08-04 |
| Cory Kasimov | Evercore ISI | Buy | USD 535 | 2026-08-04 |
| Andy Chen | Wolfe Research | Buy | USD 557 | 2026-08-03 |
| Brian Skorney | Robert W. Baird | Sell | USD 350 | 2026-07-07 |
| Unknown Analyst | Raymond James | Hold | N/A | 2026-06-24 |
| Unknown Analyst | Guggenheim | Buy | USD 546 | 2026-06-02 |
| Hans Engel | Erste Group | Hold | N/A | 2026-05-05 |
| Nico Chen | DBS | Buy | USD 540 | 2026-01-19 |
| David Risinger | Leerink Partners | Buy | USD 525 | 2025-12-29 |
Investment strengths
High-quality profitability and cash generation
Vertex combines substantial revenue with unusually strong margins and cash conversion, giving it internal funding capacity for research, launches and business development. This financial strength can support investment through development cycles while reducing reliance on external financing over the next several quarters.
Durable cystic fibrosis franchise growth
The CF franchise continues to expand through uptake of ALYFTREK, supporting recurring demand from patients using chronic therapies. Growth in the established franchise provides a durable commercial base and creates resources to fund Vertex’s newer launches and pipeline programs.
Pipeline diversification and launch execution
Progress across cell therapy, pain, renal disease and other clinical programs reduces reliance on a single future product while broadening Vertex’s potential commercial base. Continued launches and advancing studies create multiple avenues for growth beyond its historical CF concentration.
People also ask
What is the 12-month price target for Vertex Pharmaceuticals (VRTX)?
tipranks publishes an average 12-month price target of USD 589.45 (Potential Growth = 12.51%), as read on 2026-10-26. The highest target is USD 667 and the lowest is USD 442. A price target is an analyst’s estimate of where a share might trade, not a promise, and CariBroker gives no investment advice.
How many analysts cover Vertex Pharmaceuticals (VRTX)?
tipranks records 24 analyst ratings: 21 buy, 3 hold and 0 sell, which it summarises as “Strong Buy”, as read on 2026-10-26.
What is the tipranks score for Vertex Pharmaceuticals (VRTX)?
tipranks scores it 8 out of 10 and calls that “Outperform”, as read on 2026-10-26. The score is tipranks’s, not CariBroker’s, and CariBroker does not rate listed shares.
Is this CariBroker’s own forecast for Vertex Pharmaceuticals?
No. Every figure on this page is published by tipranks, copied on 2026-10-26 with a link to the original, and not recalculated. CariBroker checks financial companies in Malaysia against the public registers; it makes no forecast of its own and holds no licence to advise on securities.
Disclaimer
CariBroker provides information only and does not provide investment, financial or legal advice.
Check another company
Search every bank, broker and alert list in one place
